IVERMECTIN & FENBENDAZOLE Success Story in Canine Cancer (Sarcoma)
— William Makis MD (@MakisMD) September 30, 2024
I love sharing these, they warm my heart! 🙏
There is no stopping this paradigm shift in Cancer, no matter how hard they try to suppress it
We're entering a new era in Cancer Care.
Even for man's best friend. pic.twitter.com/ZI4COOwPLQ
In the ever-evolving landscape of veterinary oncology, the exploration of alternative treatments for canine cancers has captured the interest of pet owners and researchers alike. Among the treatments gaining traction are two drugs primarily known for their antiparasitic properties: Ivermectin and Fenbendazole. As of October 2024, the buzz around these compounds continues to grow, especially within communities on platforms like X, where success stories and shared experiences are common. Let’s delve into what we currently understand about their use in treating canine cancer.
The Science Behind Ivermectin
Ivermectin has been highlighted for its potential anticancer properties, not just in humans but also in dogs. Recent studies have indicated its ability to inhibit the proliferation of canine mammary tumor cells by affecting cell cycle progression without significantly inducing apoptosis. This mechanism involves the downregulation of the Wnt signaling pathway, crucial for cell growth regulation. Furthermore, Ivermectin’s role in converting “cold” tumors into “hot” ones, which are more responsive to immune therapies, has been noted in breast cancer models. This could potentially enhance the effectiveness of treatments like checkpoint inhibitors, suggesting a broader application in various cancer types.
Fenbendazole’s Role in Cancer Treatment
Fenbendazole, typically used as an anthelmintic, has also caught the eye of researchers for its anticancer effects. While direct studies on its efficacy in canine cancers are less abundant, general research points towards its ability to interfere with cancer cell microtubules, similar to how it affects parasites. This interference can lead to cell cycle arrest and apoptosis, mechanisms that could be pivotal in cancer therapy.
Anecdotal Evidence from X
The platform X has become a melting pot for sharing experiences with alternative cancer treatments for pets. Users frequently share success stories involving combinations of Ivermectin and Fenbendazole, often alongside other supplements like CBD, curcumin, and vitamins. These anecdotal reports suggest that some pets with aggressive cancers, including sarcomas, have achieved remission or significant improvement in their conditions. However, these stories, while hopeful, must be taken with caution as they lack the rigor of clinical trials.
Current Research Insights
Recent veterinary research, including studies on canine mammary tumors, has provided some empirical support for the use of Ivermectin. These studies confirm its antiproliferative effects and suggest that it might work through mechanisms like cell cycle arrest and modulation of immune responses. For Fenbendazole, while there’s less specific data for canine cancer, its general anticancer properties observed in other models hint at its potential utility.
Conclusion: A Note of Caution
While the combination of Ivermectin and Fenbendazole shows promise, the journey from anecdotal evidence and preliminary research to establishing these treatments as standard protocols in veterinary oncology is still underway. The enthusiasm seen on platforms like X reflects a growing interest and hope, but it also underscores the need for more comprehensive, well-controlled studies.
For now, pet owners considering these treatments should approach with informed skepticism, ideally under veterinary supervision. The path forward involves navigating the thin line between groundbreaking innovation and unproven remedies, all in the quest to combat one of the leading causes of death in our canine companions.